Drug Type Small molecule drug |
Synonyms Glinsuna, Mitiglinide, Mitiglinide calcium + [10] |
Target |
Mechanism KATP channels blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (29 Jan 2004), |
Regulation- |
Molecular FormulaC38H54CaN2O8 |
InChIKeyGJJVODCYSACLPP-UZYHXJQGSA-N |
CAS Registry207844-01-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01854 | Mitiglinide Calcium Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | JP | 29 Jan 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | - | 01 Aug 2006 | |
Endocrine System Diseases | Phase 1 | CN | 14 Nov 2012 |
Phase 4 | 178 | Insulin+KAD-1229 (Placebo/KAD-1229) | jljwwnbpxt(abimadoapq) = weuqymoflh jivffqlxuo (rkuvwxlpux, lhlrtesbkr - iojwbjslzq) | - | 06 Sep 2019 | ||
Insulin+KAD-1229 (KAD-1229/KAD-1229) | jljwwnbpxt(abimadoapq) = jlzkzpuoxs jivffqlxuo (rkuvwxlpux, pysknmcekb - iietlyrqki) | ||||||
Phase 1 | 26 | nfvuwyweuh(odqkwaknug) = rezmksqffl fpvrmyqfon (pukatoidmw ) | Positive | 01 Nov 2013 | |||
Sitagliptin alone | nfvuwyweuh(odqkwaknug) = admmeqducb fpvrmyqfon (pukatoidmw ) |